|
I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects. |
|
|
Stock and Other Ownership Interests - Global Advisory Board Medi-Globe |
Honoraria - Varian Medical Systems |
Consulting or Advisory Role - AstraZeneca |
Research Funding - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Varian Medical Systems |
|
|
Honoraria - AstraZeneca/MedImmune |
Speakers' Bureau - Varian Medical Systems |
Research Funding - Genentech/Roche; Hitachi Chemical; New River Labs; STCube Pharmaceuticals Inc. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Varian Medical Systems |
Speakers' Bureau - Varian Medical Systems |
Travel, Accommodations, Expenses - Varian Medical Systems |
|
|
Consulting or Advisory Role - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
Employment - MD Anderson Cancer Center; MD Anderson Cancer Center |
Leadership - MolecularMatch; MolecularMatch |
Stock and Other Ownership Interests - Alpine Immune Sciences; Checkmate Pharmaceuticals; Mavupharma; MolecularMatch; Nanobiotix; Nanorobotix; Oncorena; Reflexion Medical; Reflexion Medical |
Honoraria - Aileron Therapeutics; American Association of Physicists in Medicine; Nanobiotix; Reflexion Medical; Shandong Cancer Hospital; The Korean Society for Radiation Oncology |
Consulting or Advisory Role - Alpine Immune Sciences; AstraZeneca; Checkmate Pharmaceuticals; Legion Healthcare Partners; Mavu Pharmaceutical; MolecularMatch; Oncorena; Reflexion Medical |
Research Funding - Aileron Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Checkmate Pharmaceuticals; Mavu Pharmaceutical; Merck; Nanobiotix |
Patents, Royalties, Other Intellectual Property - MolecularMatch |
Travel, Accommodations, Expenses - AACR; Aileron Therapeutics; American Society for Radiation Oncology; Gustave Roussy Cancer Center; IASLC; MedAustron; Nanobiotix; Radiation Research Society; Reflexion Medical; Shandong Cancer Hospital; The Korean Society for Radiation Oncology; The Korean Society for Radiation Oncology; The Korean Society for Radiation Oncology; Turkish Society of Lung Cancer |
|
|
Honoraria - Varian Medical Systems; ViewRay |
Consulting or Advisory Role - Varian Medical Systems; ViewRay |
Research Funding - AstraZeneca; ViewRay |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie |
|
|
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Lilly; Sanofi/Aventis; Spectrum Pharmaceuticals; Syntha Pharmaceutical; Takeda |
Research Funding - AstraZeneca (Inst); Bayer; GlaxoSmithKline; Spectrum Pharmaceuticals |
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations |